A Problem of Late Diagnosis: Case Report with Polypharmacy

Jacqueline Désirée JACK, Michael SCHIRMER*

Rheumatology Research Group, Medical University Innsbruck, Department of Internal Medicine, Clinic II, Innsbruck, Austria

*Corresponding author: Michael Schirmer, MD, Associate Professor, Rheumatology Research Group, Medical University Innsbruck, Department of Internal Medicine, Clinic II, Innsbruck, Anichstrasse 35, A-6020, Austria.

Received: September 15, 2021 Published: October 13, 2021

Summary

A 49-years old, HLA-B27-negative female patient presented with inflammatory low back pain since age of 26 years and “failed back surgery syndrome” since age of 39 years. She recurrently suffered from additional arthritis, enthesitis and tenovaginitis, leading to imaging-based diagnosis of spondyloarthritis with a diagnostic delay of 23 years. NSAIDs and glucocorticoids rapidly improved her symptoms, and 11 out of the more than 18 initial tablets and capsules for pain management, central nervous disease and possible side-effects could be reduced within the following 14 months after diagnosis. Accordingly, medication costs for management of pain and gastrointestinal side-effects were reduced by a calculated 1.63 - 2.27 € per day (=595.00 - 828.55 € per year).

Polypharmacy in an undiagnosed pain patient should be considered as a red flag indicating the need for a multidisciplinary diagnostic approach. Treatment of an underdiagnosed rheumatic disease may effectively reduce polypharmacy.

Keywords: Polypharmacy; Early-diagnosis; Spondylarthritis

Background

Spondylarthritis (SpA) is a chronic immune-mediated rheumatic disease with a European prevalence between 0.2-1.6 % [1]. As both functional and structural changes have an important impact on pain and reduction of life quality [2], early diagnosis is important. Non-steroidal antirheumatic drugs (NSAIDs) are recommended as first line treatment to achieve remission or at least low disease-activity [3]. COX2-selective NSAIDs are available for patients prone to gastrointestinal side-effects, with at least comparable efficacy to conventional NSAIDs [4]. Celecoxib, one of the COX2-selective NSAIDs, was shown to retain structural disease progression when applied continuously compared to on request [5]. Etoricoxib, another COX2-selective NSAID, showed an even superior analgesic effect in rheumatoid arthritis when compared to naproxen, a non-selective COX-inhibitor [6]. Side-effects and lack of efficacy of unspecific NSAIDs may lead to extended treatment of SpA using the more potent biologicals (like inhibitors of TNF-alpha and interleukin-17) [7].

Case Presentation

This 49-year-old woman was referred to the outpatient clinic for rheumatology because of persisting diffuse pain. Erythrocyte sedimentation rate and C-reactive protein levels were repeatedly tested normal. She took 28 +½ +⅓ tablets or capsules at her 1st visit (Table 1), thus clearly fulfilling the criteria for polypharmacy.

First visit

The patient described lumbosacral pain radiating on the back side of the leg down to the knees. The maximum of pain happened at night-time and interrupted her sleep between 2.00 to 3.00 a.m. Pain worsened when sitting for a longer period of time and improved with movement. The first symptom of such inflammatory back pain was 23 years ago – at age of 27 years, with insidious onset. Eleven years before this first visit, she had ongoing pain after surgical intervention with spondylodesis of L3-S1, diagnosed as “failed back surgery syndrome”. Pain was insufficiently managed with more than 18 tablets and capsules other than NSAIDs (Table 1). At clinical examination, she had swelling over the left trochanter and pulling pain in the hip joint. The finger-to-floor-distance was 35cm. Previously performed Magnetic Resonance Images (MRIs) showed the fused L3-S1 vertebrae, alongside with an effusion in the sacroiliac joint and edema in the sacrum and caudal ilium. Elevation of shoulders was only possible...
after passive mobilisation. The MRIs of shoulders and arms revealed several effusions of joints and tendons. Examination further revealed muscular dysbalances in the neck and thighs. For the past 2 years, the patient suffered from intense headache. Comorbidities included obesity (with body mass index of 33.1 kg/m²), osteoarthritis of the knees with rupture of the anterior cruciate ligament, diabetes mellitus type II, and a bipolar affective disorder. At age of 42 years, she suffered from a transient ischemic attack and was tested with an elevated lipoprotein (a) level of 381.9 nmol/L. Her history further included several abdominal surgeries including stomach adjustments, as well as a meniscus surgery in the right knee. She had never smoked and does not drink any alcohol. With inflammatory back pain since age of 26 years, diagnosis of “failed back surgery syndrome” at age of 39 years and other findings, including typical MR-images, diagnosis of axial SpA was considered despite HLA-B27 negativity, and naproxen, a non-selective NSAID, recommended for inflammatory back pain and low-dose corticosteroids (methylprednisolone) because of the effusions of joints and tendons. A proton pump inhibitor was recommended as ulcer prophylaxis.

**Second follow-up, 4 months after first visit**

Under treatment with naproxen and methylprednisolone, sleep disturbances, hip and lumbar sacral pain improved, so physiotherapy could be started to treat the muscular dysbalances. After 2-3 weeks of treatment with the non-selective NSAID, however, gastrointestinal side-effects occurred, and the patient stopped naproxen and methylprednisolone as well as physiotherapy. She restarted her previous analgesics metamizole and hydromorphone, but without the positive effect of naproxen. She had also stopped physiotherapy and now presented again with increased pain symptoms. At this visit, with characteristic inflammatory low back pain, responsive to NSAIDs and the typical MR-images, diagnosis of axial SpA was confirmed. The shared decision was made to start with the COX2-selective NSAID etoricoxib because of her gastrointestinal complaints.

**Third follow-up, 6 months after first visit**

She presented with still ongoing symptoms, and increased pain without swelling of joints. Again, analgesics without NSAIDs were not successful, as payment of etoricoxib had not been approved by the insurance company. Etoricoxib is routinely refunded only for painful osteoarthritis in patients older than 65 years, with gastric ulcer in the history, or under anticoagulation. A second prescription for etoricoxib was made after successful negotiation with the insurance company.

**Fourth and fifth follow-up, 12 and 18 months after first visit**

After diagnosis of SpA and 1 year of treatment with the COX2-selective NSAID, pain-related medication other than NSAIDs had been slowly reduced by 10 tablets, and pantoprazole was stopped (Table 1). Physiotherapy and dietary efforts for weight loss were still ongoing.

**Discussion**

This woman was newly diagnosed with SpA at age of 50 years, after 23 years of pain symptoms without diagnosis. Even surgery was performed but ineffective, with subsequent diagnosis of “failed back surgery syndrome”. The diagnostic delay is remarkable, as literature reports a mean delay of “only” 6.8 years of “failed back surgery syndrome”. The diagnostic delay is reduced, as literature reports a mean delay of “only” 6.8 years. When “failed back surgery syndrome” at age of 39 years and other findings, including typical MR-images, diagnosis of axial SpA was confirmed. The shared decision was made to start with the COX2-selective NSAID etoricoxib because of her gastrointestinal complaints.

<table>
<thead>
<tr>
<th>Medication</th>
<th>1st, 2nd, 3rd visit</th>
<th>4th visit</th>
<th>5th visit</th>
<th>6th visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone ret 4 mg</td>
<td>1/1/1/0</td>
<td>1/1/0/0, reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone ret 2 mg</td>
<td>1/0/1/0</td>
<td>0/0/1/0, reduced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone 2.6 mg</td>
<td>1/0/1/0</td>
<td>stopped</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metamizole 500 mg</td>
<td>1/1/1/0</td>
<td>stopped</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escitalopram 5 mg</td>
<td>2/1/0/0, reduced</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valproic acid ret 3x500mg</td>
<td>2x150mg, reduced</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quetiapine 25 mg</td>
<td>0/0/0/½</td>
<td>unchanged</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trazodone ret 150 mg</td>
<td>0/0/0/½</td>
<td>unchanged</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantoprazole 40 mg</td>
<td>1/0/1/0</td>
<td>stopped</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily tablets</td>
<td>18+½+½</td>
<td>minus 11 tablets</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: List of more than 18 daily analgesics, central nervous and other medications before, and after diagnosis of spondyloarthritis with start of etoricoxib 60mg in the evening (+1 tablet). 11 tablets or capsules were reduced during 3rd and 6th visit (depicted in bold letters). Additional 10 tablets (cardiovascular, antidiabetic and thyroid medications) are not listed and remained unchanged. ret, retard preparation.

**Citation:** Jacqueline Désirée JACK, Michael SCHIRMER*. A Problem of Late Diagnosis: Case Report with Polypharmacy.

**DOI:** 10.46998/IJCMCR.2021.13.000325

**Volume 13- Issue 5**
In conclusion, this report supports the need of diagnosis in multidisciplinary settings especially for patients with polypharmacy.

**Take Home Messages**
- Polypharmacy may be high in pain patients without underlying diagnosis. In these patients, a multidisciplinary diagnostic approach including a rheumatologist can be successful.
- The diagnostic delay for spondyloarthritis can be still prolonged over years, despite all efforts made to allow earlier diagnosis and treatment.
- Effective treatment of spondyloarthritis can improve pain, disease activity and life quality with reduced number of medications, thus reducing polypharmacy and saving money in health care systems over the long-term.

**Conflicts of interest:** None

**Financial support:** None

**References**